Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream.

Literature DB >> 21607193

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream.

Joshua A Zeichner¹, Rita V Patel, Miriam B Birge.

Abstract

Basal cell carcinoma is the most common form of nonmelanoma skin cancer in the United States. Treatment modalities include both surgical, medical, or combination therapy. In the following case, the authors report the successful treatment of a basal cell carcinoma on the nose with curettage followed by topical imiquimod 3.75% cream.

Entities: Disease

Year: 2011 PMID： 21607193 PMCID： PMC3100110

Source DB: PubMed Journal: J Clin Aesthet Dermatol ISSN： 1941-2789

21 in total

1. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.

Authors: John Geisse; Ivor Caro; Jane Lindholm; Loren Golitz; Patti Stampone; Mary Owens
Journal: J Am Acad Dermatol Date: 2004-05 Impact factor: 11.527

2. Combined curettage and excision: a treatment method for primary basal cell carcinoma.

Authors: T M Johnson; T A Tromovitch; N A Swanson
Journal: J Am Acad Dermatol Date: 1991-04 Impact factor: 11.527

Review 3. Basal-cell carcinoma.

Authors: Adam I Rubin; Elbert H Chen; Désirée Ratner
Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245

4. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.

Authors: Jason K Wu; Carol Oh; Geoff Strutton; Greg Siller
Journal: Australas J Dermatol Date: 2006-02 Impact factor: 2.875

5. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.

Authors: C William Hanke; Kenneth R Beer; Eggert Stockfleth; Jason Wu; Theodore Rosen; Sharon Levy
Journal: J Am Acad Dermatol Date: 2010-02-04 Impact factor: 11.527

Review 6. Imiquimod applied topically: a novel immune response modifier and new class of drug.

Authors: R L Miller; J F Gerster; M L Owens; H B Slade; M A Tomai
Journal: Int J Immunopharmacol Date: 1999-01

7. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.

Authors: Neil Swanson; William Abramovits; Brian Berman; James Kulp; Darrell S Rigel; Sharon Levy
Journal: J Am Acad Dermatol Date: 2010-02-04 Impact factor: 11.527

8. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.

Authors: Stephen Shumack; June Robinson; Steven Kossard; Loren Golitz; Hubert Greenway; Arnold Schroeter; Kara Andres; Mark Amies; Mary Owens
Journal: Arch Dermatol Date: 2002-09

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream.

1. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.

2. Combined curettage and excision: a treatment method for primary basal cell carcinoma.

Review 3. Basal-cell carcinoma.

4. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.

5. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.

Review 6. Imiquimod applied topically: a novel immune response modifier and new class of drug.

7. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.

8. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.

9. 15 years' experience with treatment of basal cell carcinomas of the skin with curettage.

10. Nonsurgical treatment options for Basal cell carcinoma.

Review 1. Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

2. Bibliometric analysis of toll-like receptor agonists associated with cancer therapy.